#Denmark #Lundbeck #bexicaserin #Valby #Deep Ocean

Lundbeck Marks Key Progress in DEEp OCEAN Clinical Trial

Lundbeck has hit a significant milestone with the randomization of the last patient in the DEEp OCEAN trial, a globally conducted Phase III clinical study aimed at evaluating the investigational drug bexicaserin. This study targets seizures associated with developmental and epileptic encephalopathies (DEEs), a group of severe epilepsy conditions that primarily affect children and are marked by frequent seizures and developmental delays.

A Comprehensive Approach to DEEs

The DEEp OCEAN trial is notable for its breadth, aiming to encompass a wide range of DEE syndromes that, historically, have been challenging to treat due to the lack of approved medications. Many of these syndromes, such as Dravet syndrome and Lennox–Gastaut Syndrome, leave patients in need of effective therapies. By enrolling over 350 participants aged between 2 and 65 years, researchers are hoping that the findings will translate to better management and understanding of seizures linked to these complex conditions.

Professor Ingrid Scheffer, the lead investigator, highlighted that DEEp OCEAN is the most expansive pivotal study of its kind, incorporating diverse genetic profiles and syndromes reflective of real-life scenarios faced by patients. The trial is designed as a placebo-controlled, multicenter endeavor, which will not only evaluate the safety and efficacy of bexicaserin but also its tolerability among patients of varying ages.

Bexicaserin and its Unique Mechanism

Bexicaserin stands out as a novel oral treatment, acting as a highly selective superagonist of the 5-HT2C receptor, which plays a crucial role in modulating seizure activity. Its dual mechanism increases inhibitory neuron signaling while reducing excitatory neuron function. This unique action is designed to enhance the drug's efficacy while potentially minimizing side effects often seen with other treatments. Preliminary results from earlier studies have shown promise, suggesting a reduction in seizure frequency across different DEE types.

Lundbeck has previously secured Breakthrough Therapy Designation for bexicaserin in both the United States and China, underscoring the urgent need for new treatment alternatives in the DEE space. This designation aims to expedite its development, acknowledging the significant unmet medical needs of patients.

What Lies Ahead

As the DEEp OCEAN trial moves forward, participants will transition into an open-label extension for those eligible, potentially allowing long-term access to bexicaserin. Results from the trial are expected to be released at the end of 2026 or early 2027, promising to shed light on new treatment avenues for DEEs.

Furthermore, Lundbeck is committed to its continuing DEEp SEA trial specifically focused on Dravet syndrome, aiming to enhance recruitment and clinical understanding of this rare condition.

The progress marked by the DEEp OCEAN trial reiterates the dedication of Lundbeck to addressing neurological disorders and improving patient outcomes, as they continue to explore innovative therapies in the field of brain health.

Conclusion

The completion of patient randomization in the DEEp OCEAN trial is more than just a step in the research process; it reflects hope for countless families affected by debilitating conditions like DEEs. With ongoing trials and a strong commitment to patient care, Lundbeck is at the forefront of bringing meaningful change to the landscape of epilepsy treatments.